Ongoing challenges for pharmacotherapy for dyslipidemia

@article{Pisaniello2015OngoingCF,
  title={Ongoing challenges for pharmacotherapy for dyslipidemia},
  author={Anthony D. Pisaniello and Daniel J. Scherer and Yu Kataoka and Stephen J Nicholls},
  journal={Expert Opinion on Pharmacotherapy},
  year={2015},
  volume={16},
  pages={347 - 356}
}
  • Anthony D. Pisaniello, Daniel J. Scherer, +1 author Stephen J Nicholls
  • Published 2015
  • Medicine
  • Expert Opinion on Pharmacotherapy
  • Introduction: While increasing evidence has led to lipid-modifying therapy achieving an important role in the treatment guidelines for the prevention of cardiovascular disease, these agents are suboptimally used and there remains a considerable risk of clinical events. Accordingly, there is a need to develop more effective lipid-modifying approaches in many patients. Areas covered: A literature search was performed of topical manuscripts focusing on factors influencing use of established… CONTINUE READING

    Topics from this paper.

    Citations

    Publications citing this paper.
    SHOWING 1-5 OF 5 CITATIONS

    Defining the Role of PCSK9 Inhibitors in the Treatment of Hyperlipidemia

    VIEW 1 EXCERPT
    CITES BACKGROUND

    Current lipid-modifying agents

    VIEW 4 EXCERPTS
    CITES BACKGROUND & METHODS
    HIGHLY INFLUENCED

    Sobetirome: the past, present and questions about the future

    VIEW 2 EXCERPTS
    CITES BACKGROUND

    2016 Russell Ross Memorial Lecture in Vascular Biology: Molecular–Cellular Mechanisms in the Progression of Atherosclerosis

    • Ira Tabas
    • Medicine
    • Arteriosclerosis, thrombosis, and vascular biology
    • 2017
    VIEW 1 EXCERPT
    CITES BACKGROUND

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 122 REFERENCES

    Lipid lowering with PCSK9 inhibitors

    VIEW 1 EXCERPT

    Dalcetrapib: a review of Phase II data

    VIEW 1 EXCERPT